English | Español

Janssen Biotech, Inc.
+ Regulatory
Nicholas Gueguen | Aug 17, 2017

FDA gives Imbruvica go-ahead to aid patients with chronic graft versus host disease
+ Technology/Innovation
Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia
+ Technology/Innovation
Jamie Barrand | Sep 17, 2015

Janssen's multiple myeloma drug accepted for FDA priority review

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes